37185251|t|Kymriah  (tisagenlecleucel) - An overview of the clinical development journey of the first approved CAR-T therapy.
37185251|a|The emergence of cell and gene therapies has dramatically changed the treatment paradigm in oncology and other therapeutic areas. Kymriah  (tisagenlecleucel), a CD19-directed genetically modified autologous T-cell immunotherapy, is currently approved in major markets for the treatment of relapsed/refractory (r/r) pediatric and young adult acute lymphoblastic leukemia, r/r diffuse large B-cell lymphoma, and r/r follicular lymphoma. This article presents a high-level overview of the clinical development journey of tisagenlecleucel, including its efficacy outcomes and safety considerations.
37185251	100	105	CAR-T	Gene	9607
37185251	276	280	CD19	Gene	930
37185251	456	484	acute lymphoblastic leukemia	Disease	MESH:D054198
37185251	490	519	diffuse large B-cell lymphoma	Disease	MESH:D016403
37185251	529	548	follicular lymphoma	Disease	MESH:D008224

